The milestone payments from MSD would be only for Pain and cognition drugs in the pipelines. The proposed BNC105 clinical trial for cancer treatment would need to be funded somewhere else, thus this presentation to the investors.
Ann: Bionomics Presents at Biotech Showcase 2017, page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)